SCHEMBL7065621

SCHEMBL7065621

Cc1cc(N2CCCC2C)n2nc(-c3ccc(Cl)cc3)cc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.56
NPC1 O15118 7/20 0.56
HPGD P15428 6/20 0.56
RAB9A P51151 6/20 0.56
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HTT P42858 2/20 0.56
MAPT P10636 4/20 0.53
NPSR1 Q6W5P4 2/20 0.53
LMNA P02545 3/20 0.49
KMT2A Q03164 2/20 0.47
TAAR1 Q96RJ0 1/20 0.47
TP53 P04637 3/20 0.45
HSD17B10 Q99714 3/20 0.45
MAPK1 P28482 3/20 0.42
GAA P10253 1/20 0.42
MTOR P42345 2/20 0.41
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7063816 0.97 KDM4E (0.57) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7061181 0.81 NPC1 (0.64) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL21749184 0.80 KDM4E (0.61) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7066787 0.80 NPC1 (0.63) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7269309 0.76 KDM4E (0.63) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7066040 0.76 KDM4E (0.63) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL21775874 0.76 KDM4E (0.78) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7061171 0.75 MAPK8 (0.63) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7061175 0.75 MAPK8 (0.63) KDM4ENPC1HPGDRAB9AALDH1A1
SCHEMBL7067713 0.75 MAPK8 (0.63) KDM4ENPC1HPGDRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649759-B2 Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders PFIZER INC. 2003-11-18 US claimed
US-20030100546-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2003-05-29 US claimed
US-20020061897-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2002-05-23 US claimed
US-6649759-B2 Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders PFIZER INC. 2003-11-18 US disclosed
US-20030100546-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2003-05-29 US disclosed
US-20020061897-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100546-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR KDM4E 3423/4885NPC1 536/4885HPGD 2042/4885
US-20020061897-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR KDM4E 3423/4885NPC1 536/4885HPGD 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.